BuzzRx Launches 'Bee Healthy' Scholarship Program to Empower the Next Generation of Health Leaders
FORT WALTON BEACH, FL / / May 16, 2025 / Prescription discount provider BuzzRx recently introduced the first-annual BuzzRx Bee Healthy Scholarship Fund, a new initiative to provide scholarships to qualified students pursuing a healthcare-related career.
"The next generation of health leaders will play a critical role in helping Americans across the country live healthier lives," says Matthew Herfield, co-founder and CEO of BuzzRx. "Creating a healthier nation relies on the power of community - doctors, pharmacists and those who work together to improve healthcare for all. Unfortunately, the high cost of education can make the journey to a professional healthcare career difficult for many students."
According to the Education Data Initiative, 73% of medical school graduates go into debt, with 31% also accruing educational debts from their premedical school education. Rising rates of education-related debt can make it challenging for young healthcare professionals to establish themselves and gain financial stability. In this environment, every bit of financial assistance helps.
In what Herfield hopes will be the start of an annual scholarship fund, BuzzRx is offering four $5,000 scholarships for undergraduate or graduate students who are working to improve the health of their communities. Scholarships will be awarded for the fall 2025 semester.
The BuzzRx Bee Healthy Scholarship aims to give back to students pursuing one of several career paths in healthcare, including pharmacists, doctors, nurses, public health professionals, healthcare policymakers, business administrators and even healthcare engineers and data scientists.
"Each career path plays a powerful role in improving health outcomes for everyday Americans," Herfield says. "From pharmacists who ensure proper medication management to administrators who enact policies that improve the efficiency of local health systems, everyone has a part to play. These symbiotic relationships, focused on the greater good of our communities, are why our scholarship isn't limited to a particular occupation within healthcare. We want to provide scholarship assistance to eligible candidates who are helping lay the foundation for better health in their community."
Students who wish to apply for the BuzzRx Bee Healthy Scholarship must be enrolled as full-time undergraduate or graduate students at an accredited college or university, maintain a GPA of 3.0 or higher and be part of a program with an emphasis on healthcare.
In addition to nursing school, medical school and pharmacy school students, undergraduate students who are currently enrolled in pre-medical coursework or business school students with an interest in healthcare may also qualify. STEM program students who have an active interest in healthcare are also encouraged to apply.
As part of the application process, qualified students are required to submit a 500-word maximum essay, as well as upload an accompanying two-minute maximum video to YouTube, Facebook, Instagram or TikTok that tags BuzzRx and uses the hashtag #BeeHealthyScholarship.
"We encourage students who share our passion for health and wellness to apply," Herfield explains. "The essay prompt invites students to share how they have impacted the health and well-being of others in their community - it could be through an ongoing initiative or a specific notable action. Ultimately, we want students to demonstrate how they are making a positive change in the healthcare space. We encourage applicants to be creative, especially with their videos, in how they use storytelling and visuals to share their love for healthcare and their passion for giving back."
Scholarship applications are open now until June 27, 2025. Applicants will be reviewed after this time, with scholarship winners contacted directly by BuzzRx in August 2025. Scholarships must be used for tuition and books. The scholarships are non-renewable, and in an effort to provide assistance to as many future health leaders as possible, individuals may only win a BuzzRx Bee Healthy Scholarship once in their lifetime.
Additional information, including application instructions, may be found on the BuzzRx Scholarship Program website. Questions about the scholarship program and the essay contest can be emailed to scholarships@buzzrx.com.
About BuzzRx
Founded in 2010, BuzzRx is a free prescription discount service that allows users to instantly find the lowest price on their medication at over 60,000 pharmacies nationwide. The website and free mobile app promote drug transparency by allowing users to compare discounted prices across pharmacy chains, helping reduce out-of-pocket costs and sticker shock at the counter. Since 2021, BuzzRx has helped over 10 million people in the U.S. save up to 80% on their medications, resulting in $2 billion saved. BuzzRx also supports its nonprofit partners year-round, donating over $10 million. For more information, visit BuzzRx.com or download the free mobile app on iOS and Android.
Media Details
Company Name: BuzzRx LLCEmail Address: press@buzzrx.comWebsite URL: https://www.buzzrx.com/
SOURCE: BuzzRx
View the original press release on ACCESS Newswire
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Epoch Times
5 hours ago
- Epoch Times
Why Drug Price Reform Alone Won't Heal America
President Donald Trump's revived effort to reduce prescription drug prices is a long-overdue step toward affordability. For millions of Americans, the cost of staying alive has become burdensome, and any policy that eases the burden is worth celebrating. However, as a physician, I've seen what happens when medications become too cheap, plentiful, and automatic. If we don't reform how drugs are used, we risk trading financial hardship for clinical harm. Vagaries of Lower Drug Costs In today's health care system, medication is the first answer—and often the last, especially for older adults. More than 40
Yahoo
10 hours ago
- Yahoo
Psychedelics as potential mental health treatment are explored by Trump administration
The Trump administration has expressed interest in exploring psychedelics for their potential in treating PTSD and other debilitating mental health issues, various officials have shared. "The Department shares the goal of ensuring that all Americans — especially our nation's veterans — have access to safe and effective treatments for conditions such as PTSD, addiction and depression," a spokesperson for the U.S. Department of Health and Human Services (HHS), run by Sec. Robert J. Kennedy Jr., said in a statement provided to Fox News Digital. "Secretary Kennedy is committed to applying rigorous, evidence-based science to research efforts aimed at addressing these serious health challenges." Fda Approves First Ai Tool To Predict Breast Cancer Risk In recent years, researchers have been actively investigating the potential of psychedelics, such as MDMA and psilocybin ("magic mushrooms") to treat mental health disorders. MDMA is not approved for clinical use by the U.S. Food and Drug Administration (FDA), but can be studied in clinical settings. Read On The Fox News App Psilocybin is listed as a Schedule I substance under the Controlled Substances Act, which means it has "a high potential for abuse, [is not] currently accepted for medical use in treatment in the United States, and [has] a lack of accepted safety for use under medical supervision." Psilocybin-assisted therapy, however, is legal in Oregon, Colorado and New Mexico. Psychedelic medicines are "showing real promise," according to Dr. Luke Twelves, general practitioner and vice president of medical for Lindus Health in London. Clinical trials have found such treatments safe and effective for patients battling serious mental health issues, according to Twelves. Common Supplements And Medications Could Cause Liver Damage, Studies Show "Take psilocybin, for example — it's demonstrating remarkable results for severe depression that hasn't responded to other medications," he told Fox News Digital. "MDMA is showing similar breakthroughs for PTSD treatment." Clinical trials are also investigating how psychedelics could help with end-of-life anxiety, addiction, eating disorders, chronic pain and OCD, he added. Researchers have faced challenges in terms of regulatory hurdles and proper placebo controls, Twelves said. "Given that these treatments could transform [the] lives of people suffering from conditions where nothing else has worked effectively, it's crucial that we complete this research properly," he said. "The goal is to bring safe, proven psychedelic therapies to the patients who need them most." At President Trump's May 1 cabinet meeting, Department of Veterans Affairs Secretary Doug Collins said that "we're opening up the possibility of psychedelic treatment." Retired Army Sergeant Jonathan Lubecki recently told Fox News' Alexandria Hoff that MDMA stopped his PTSD while he was participating in a clinical trial. "[I] took my first dose of MDMA. I've only taken it three times as part of the clinical trial, haven't taken it since, and haven't found the need to take it since, because I haven't had PTSD," he said. Peter Kasperowicz, Department of Veterans Affairs press secretary, told Fox News Digital the department is safely exploring all avenues that promote the health of veterans. Fallujah Vet Turns Medal Of Heroism Into A Healing Mission For Fellow Warriors With Service Dogs Program "Preliminary findings have produced positive results on psychedelic-assisted therapies for treating mental health conditions," he said. The VA is currently running 11 clinical trials in various phases, with a total of some 800 veterans expected to participate. "The goal of these trials is to determine whether compounds such as MDMA and psilocybin can treat veterans with post-traumatic stress disorder, treatment-resistant depressive disorder, major depressive disorder and potentially other mental health conditions," said Kasperowicz. An MDMA study published in the Jan. 2025 issue of The American Journal of Psychiatry found that the substance is "unlike classical psychedelics." The study noted, "MDMA allows the individual to maintain intact ego functioning and a greater degree of cognitive and perceptual lucidity while still experiencing a prosocial altered state of consciousness that facilitates deeply emotional therapeutic breakthroughs." Click Here To Sign Up For Our Health Newsletter The researchers concluded that MDMA showed "enhanced levels of trust, empathy, self-compassion and a 'window of tolerance'" that traditional psychotherapy lacks. Doug Drysdale, CEO of the Canadian pharmaceutical company Cybin, told Fox News Digital that "the time is now to address the mental health crisis." He said it is "gratifying" that administration officials value the potential benefits of looking into alternative mental health treatments. Cybin is currently in phase 3 of a study of CYB003, a type of psilocybin that has been granted breakthrough therapy designation by the FDA as an additional treatment for major depressive disorder (MDD). "In Cybin's completed Phase 2 MDD study, long-term efficacy results showed that 71% of participants were in remission from depression, and 100% of participants responded to treatment at 12 months after just two 16 mg doses of CYB003," said Drysdale. Dr. Marc Siegel, clinical professor of medicine at NYU Langone Medical Center and Fox News' senior medical analyst, previously interviewed two of the country's top researchers on psychedelics — Dr. Rachel Yehuda, founder and director of the Center for Psychedelic Psychotherapy and Trauma Research at Mt. Sinai in New York, and Dr. Charles Marmar, director of the PTSD research program at NYU Langone. "They agree there is therapeutic potential if very carefully studied under very strict medical guidance, but there is a huge downside in terms of unregulated recreational uses," Siegel told Fox News Digital at the time. "Both doctors see likely therapeutic value to psychedelics if carefully managed by medical experts," Siegel added. Ryan Moss, chief science officer at Filament Health, a clinical-stage natural psychedelic drug development company in Canada, emphasized it's important to administer psychedelics in a safe setting when treating mental health conditions. For more Health articles, visit "Psychedelic experiences can sometimes feature anxiety, hallucinations and paranoia," Moss previously told Fox News Digital. "Some patients using traditional psychedelics have reported experiencing adverse cardiovascular events during clinical trials." To mitigate these risks, Moss recommended clinical trial participants receive thorough preparation and monitoring by trained professionals during sessions. Melissa Rudy and Angelica Stabile, both of Fox News Digital, contributed article source: Psychedelics as potential mental health treatment are explored by Trump administration
Yahoo
11 hours ago
- Yahoo
Opinion - How thousands of unreviewed ingredients got into our food — and what FDA can do about it
At least 1,000 ingredients in food products on our grocery store shelves have never been checked for safety by the Food and Drug Administration. Dozens have raised serious safety concerns among experts. How did the FDA allow this? The answer can be found in the agency's lax interpretation of a little-known legal designation that lets companies decide for themselves if ingredients in their products are safe. Fortunately, there are steps the agency can take right now to stem the flow of potentially unsafe ingredients into our food supply. Environmental Defense Fund outlined these steps in a letter we recently sent to the agency, but first let's take a closer look at how we got here. 'Generally Recognized as Safe' is a designation Congress created in 1958 to allow commonly used food ingredients to bypass the FDA's pre-market safety review process. It was meant for food substances — such as oils, vinegar, baking soda and common spices — that were widely considered safe due to their long history of everyday use. Since 1958, this status has been coopted to cover a universe of foods that extends far beyond its original intent. According to FDA regulations, a chemical can receive the designation if experts widely agree that scientific evidence shows its use to be safe. But because 'Generally Recognized as Safe' wasn't meant for newer ingredients, Congress allowed ingredients so designated to skip the FDA's premarket approval process — despite requiring similar evidence for other additives. Under the agency's current interpretation, companies can designate the use of a substance as safe and take products with that substance to market without informing the FDA or the public of its decision. While companies may voluntarily submit a notice to FDA offering safety evidence, they are not required to — and often don't. Our organization estimated that manufacturers have notified FDA of fewer than half of the ingredients they market as safe under the 'Generally Recognized' standard. Companies that do bother to submit a notice to the FDA are free to withdraw it at any point and take their product to market, provided they can cite evidence of its safe use. But this 'evidence' is often far from independent. Companies can, and often do, enlist their own employees or handpicked consultants to conduct their safety assessments. The result is a process riddled with conflicts of interest that lets unsafe foods into Americans' homes. We analyzed 'Generally Recognized as Safe' notices received by the FDA, obtained via a Freedom of Information request, and found that of the 1,163 submitted by companies between 1997 and April 2024, 192 were later withdrawn, with safety concerns cited in at least a dozen cases. We also identified 31 ingredients that companies have advertised to be recognized as safe, such as in press releases, trade publications and on their own websites (see the Appendix of our letter). However, we were unable to find the scientific evidence required under this standard to demonstrate these ingredients are commonly regarded as safe among experts. This raises red flags that FDA should be taking seriously. Although a comprehensive fix to the 'Generally Recognized' standard will require legislation from Congress, there are significant steps the FDA can take right away to ensure a more rigorous determination process that better protects Americans' health. Starting today, the FDA can use existing authority to remove safe designations from ingredients it deems unsafe and take them off the market. It can also notify manufacturers, importers, distributors and retailers that the substance is no longer recognized as safe. In addition, the FDA can enforce the requirement that companies base safety designations on publicly available data. Although this won't curtail companies' ability to self-declare substances as safe, it will require those who do to be transparent in citing their evidence. Third, the FDA can enforce the requirement that safety assessments consider vital health information such as a substance's dietary sources, potential cancer risks and the cumulative health effects of similar substances. Finally, the FDA can make companies revise and resubmit their data for review when they submit 'Generally Recognized as Safe' notices that fail to comply with the criteria. The 'Generally Recognized as Safe' designation is far from a perfect system, but it can work better if it is interpreted and enforced more comprehensively. If the FDA is serious about protecting public health, it should start by fully exercising the tools already at its disposal. Maria Doa is senior director at the Chemicals Policy at Environmental Defense Fund. Maricel Maffini is an independent consultant focused on human and environmental health and chemical safety. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
